Eva Maria Guerra Alía
YOU?
Author Swipe
View article: 44P Long-term follow-up of selinexor (SEL) maintenance treatment in patients with TP53 wild type (wt) advanced/recurrent (A/R) endometrial cancer (EC): Intermediate endpoints by mismatch repair (MMR) status in the ENGOT-EN5/GOG-3055/SIENDO study
44P Long-term follow-up of selinexor (SEL) maintenance treatment in patients with TP53 wild type (wt) advanced/recurrent (A/R) endometrial cancer (EC): Intermediate endpoints by mismatch repair (MMR) status in the ENGOT-EN5/GOG-3055/SIENDO study Open
View article: 83P Bevacizumab (Bev) in platinum-resistant ovarian cancer: Does prior exposure to bev affect outcomes? A retrospective study
83P Bevacizumab (Bev) in platinum-resistant ovarian cancer: Does prior exposure to bev affect outcomes? A retrospective study Open
View article: 58TiP ASCENT-GYN-01 (GOG-3104/ENGOT-en26): A randomized, phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with endometrial cancer (EC) after platinum-based chemotherapy and immunotherapy
58TiP ASCENT-GYN-01 (GOG-3104/ENGOT-en26): A randomized, phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with endometrial cancer (EC) after platinum-based chemotherapy and immunotherapy Open
View article: Can Morphology and Immune Infiltration Predict the Homologous Recombination Deficiency Status in Newly Diagnosed High-Grade Serous Ovarian Carcinoma?: Lessons From the PAOLA-1/ENGOT-ov25 Trial, a GINECO Study
Can Morphology and Immune Infiltration Predict the Homologous Recombination Deficiency Status in Newly Diagnosed High-Grade Serous Ovarian Carcinoma?: Lessons From the PAOLA-1/ENGOT-ov25 Trial, a GINECO Study Open
Context.— A correlation between the morphology of ovarian high-grade serous carcinomas (HGSOCs) and BRCA mutations has been previously reported. Objective.— To investigate, beyond BRCA, the association between the morphology of HGSOC and t…
View article: Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma
Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma Open
F. Hoffmann-La Roche Ltd.
View article: 65P Chemotherapy response score (CRS) and efficacy of PARP inhibitor (PARPi) treatment in advanced epithelial ovarian cancer (AEOC)
65P Chemotherapy response score (CRS) and efficacy of PARP inhibitor (PARPi) treatment in advanced epithelial ovarian cancer (AEOC) Open
BRCA 1/2 mutations (BRCAmut) and homologous recombination deficient (HRD) status are well-established prognostic and predictive factors of the magnitude of response to PARPi. CRS is also known as a prognostic value in patients with AEOC un…
View article: A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer
A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer Open
View article: 770P Tolerability and efficacy of trabectedin plus pegylated liposomal doxorubicin (PLD) in elderly patients with ovarian cancer (OC): GEICO 105-O study
770P Tolerability and efficacy of trabectedin plus pegylated liposomal doxorubicin (PLD) in elderly patients with ovarian cancer (OC): GEICO 105-O study Open
View article: Correction to: Extramammary Paget Disease: a Therapeutic Challenge, for a Rare Entity
Correction to: Extramammary Paget Disease: a Therapeutic Challenge, for a Rare Entity Open
View article: #264 Long-term follow up of selinexor maintenance for patients with TP53wt advanced or recurrent endometrial cancer: a pre-specified subgroup analysis from the phase 3 ENGOT-EN5/GOG-3055/SIENDO study
#264 Long-term follow up of selinexor maintenance for patients with TP53wt advanced or recurrent endometrial cancer: a pre-specified subgroup analysis from the phase 3 ENGOT-EN5/GOG-3055/SIENDO study Open
Introduction/Background Molecular characterization is important to inform treatment decisions for patients with endometrial cancer (EC). Wild type TP53 (TP53wt) is found in ~75% of newly diagnosed EC and 50% of advanced/recurrent tumors; t…
View article: Extramammary Paget Disease: a Therapeutic Challenge, for a Rare Entity
Extramammary Paget Disease: a Therapeutic Challenge, for a Rare Entity Open
Purpose of Review Extramammary Paget disease (EMPD) is a rare entity which is more frequently localized at the vulva, though it only accounts for 1–2% of vulvar neoplasms. It is a primary cutaneous adenocarcinoma whose cell of origin is st…
View article: Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial Open
View article: Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775
Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775 Open
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. …
View article: Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial
Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial Open
Older patients enrolled in PAOLA-1 achieved similar PFS benefits compared with younger patients, with a similar safety profile.
View article: 2022-RA-653-ESGO The impact of histology, prior therapy, and dMMR status on lenvatinib + pembrolizumab outcomes in patients with advanced endometrial cancer: A subgroup analysis of Study 309/KEYNOTE-775
2022-RA-653-ESGO The impact of histology, prior therapy, and dMMR status on lenvatinib + pembrolizumab outcomes in patients with advanced endometrial cancer: A subgroup analysis of Study 309/KEYNOTE-775 Open
View article: LBA29 Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)
LBA29 Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) Open
View article: VP2-2022: Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer
VP2-2022: Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer Open
View article: Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial Open
In PAOLA-1, maintenance olaparib plus bevacizumab provided a substantial PFS benefit in HRD-positive patients with a reduction of risk of progression or death of 61% in the higher-risk group and of 85% in the lower-risk group compared with…
View article: Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer Open
In patients with advanced ovarian cancer receiving first-line standard therapy including bevacizumab, the addition of maintenance olaparib provided a significant progression-free survival benefit, which was substantial in patients with HRD…
View article: Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev
Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev Open
View article: Maintenance with Trabectedin in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer
Maintenance with Trabectedin in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer Open
Ovarian cancer is the seventh most common type of cancer and the fifth leading cause of cancer death among women worldwide. The current usual therapeutic approach in this disease includes optimal cytoreductive therapy followed by platinum-…
View article: Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer
Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer Open
View article: Quantification of genetic variants as marker of Brca-like phenotype in ovarian cancer
Quantification of genetic variants as marker of Brca-like phenotype in ovarian cancer Open
View article: Preoperative olaparib in early-stage endometrial cancer (EC): A phase 0, window of opportunity trial to evaluate the PARP inhibition effect, targeting cell cycle-related proteins (POLEN study)
Preoperative olaparib in early-stage endometrial cancer (EC): A phase 0, window of opportunity trial to evaluate the PARP inhibition effect, targeting cell cycle-related proteins (POLEN study) Open